<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916145</url>
  </required_header>
  <id_info>
    <org_study_id>B-2009-637-306</org_study_id>
    <nct_id>NCT04916145</nct_id>
  </id_info>
  <brief_title>An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults</brief_title>
  <acronym>SAT-008</acronym>
  <official_title>A Single-center, Randomized, Open Label, No-treatment Controlled, Digital Device Study to Evaluate the Efficacy, Safety and Feasibility of SAT-008 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>S-Alpha Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this exploratory study is to evaluate the efficacy, safety, and feasibility of&#xD;
      a novel digital device called SAT-008 in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study was designed as a single institution, open, controlled, and&#xD;
      investigator-led clinical trial to evaluate the efficacy, safety, and feasibility of a novel&#xD;
      digital device called SAT-008 in healthy adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to one of two study arms. One group (treatment) will receive an experimental digital device for 13 weeks while the other group (control) will maintain daily activity as usual.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in functions of immunocytes</measure>
    <time_frame>Baseline, Week 1, Week 5, Week 13</time_frame>
    <description>To measure changes in functions of natural killer cells, T cells, and B cells at 1, 5, and 13 weeks compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of expected and unexpected adverse events</measure>
    <time_frame>Baseline</time_frame>
    <description>To evaluate the safety of SAT-008</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of expected and unexpected adverse events</measure>
    <time_frame>Week 1 (a week following baseline)</time_frame>
    <description>To evaluate the safety of SAT-008</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of expected and unexpected adverse events</measure>
    <time_frame>Week 5 (five weeks following baseline)</time_frame>
    <description>To evaluate the safety of SAT-008</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of expected and unexpected adverse events</measure>
    <time_frame>Week 13 (thirteen weeks following baseline)</time_frame>
    <description>To evaluate the safety of SAT-008</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adherence to SAT-008</measure>
    <time_frame>Week 1 (a week following baseline)</time_frame>
    <description>To assess a degree to which participants follow SAT-008</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adherence to SAT-008</measure>
    <time_frame>Week 5 (five weeks following baseline)</time_frame>
    <description>To assess a degree to which participants follow SAT-008</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adherence to SAT-008</measure>
    <time_frame>Week 13 (thirteen weeks following baseline)</time_frame>
    <description>To assess a degree to which participants follow SAT-008</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Allergy and Immunology</condition>
  <arm_group>
    <arm_group_label>No any treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomly assigned to this group will maintain a routine life without any treatments (no use of SAT-008).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Use of SAT-008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to this group will be treated by SAT-008 during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAT-008</intervention_name>
    <description>SAT-008 is a digital device containing several types of activities related to the immune function of adults.</description>
    <arm_group_label>Use of SAT-008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 19 to 50 years&#xD;
&#xD;
          -  Received influenza vaccination the previous year&#xD;
&#xD;
          -  Scheduled to receive the influenza vaccine&#xD;
&#xD;
          -  Voluntarily agrees with a consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current infectious disease&#xD;
&#xD;
          -  History of autoimmune diseases&#xD;
&#xD;
          -  Current immunological compromised diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Seok Chang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>addchang@snu.ac.kr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Yoon-Seok Chang, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

